CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 ...

Boehringer Ingelheim picked a challenging day to reveal its 2024 financial results and guidance for this year. | Boehringer ...

ZÜRICH--(BUSINESS WIRE)--CDR-Life today announced the achievement of the fifth milestone under its collaboration and licensing agreement with Boehringer Ingelheim in the advancement of BI 771716 ...